Advancing Neurotherapeutics. Transforming Lives.
NeuroSigma is a bioelectronic medical device company leveraging non-invasive trigeminal-nerve stimulation to treat chronic neurological disorders.
0
FDA Cleared Device
0
Clinical Trials
20
Patents Issued
0
+
Patients Safely Treated
NeuroSigma converts gentle, external electrical pulses into precisely targeted neuromodulation—without surgery, implants, or medication. Our technology stimulates the trigeminal nerve, a key pathway that influences brain function, mood, and attention.
This work matters: ​
​
-
Clinically Validated: Supported by 10 clinical trials and more than 2,500 patient treatments to date.
-
Science-Driven Design: Built on decades of neuroengineering research and protected by 50+ issued patents.
-
Large-Scale Impact: Addresses multi-billion-dollar neurological and neuropsychiatric markets with strong unmet needs including indications that includes autism spectrum disorder (ASD), epilepsy, and depression.
​
Our goal is clear: to make neuromodulation accessible, evidence-based, and transformative for patients and families worldwide.
The Monarch eTNS® System
The First FDA Cleared Device for Treating Pediatric ADHD.
The Monarch eTNS® System is indicated for the treatment of pediatric Attention Deficit Hyperactivity Disorder (ADHD) as a monotherapy in patients ages 7 through 12 years old who are not currently taking prescription ADHD medications.
The Monarch TNS® is available by prescription only and is intended to be used in the home under the supervision of a caregiver during periods of sleep.
Important Safety Information:​
​
Indication: Monarch eTNS® System is indicated for treatment of pediatric ADHD as a monotherapy in patients ages 7 to 12 who are not currently on prescription ADHD medications. The device is for use during sleep under the supervision of a caregiver.
Contraindications: Not for use in patients with implanted pacemakers, neurostimulators, or metallic/electronic head implants. Do not use in children under 7.
Common side effects: Drowsiness, increased appetite, insomnia, teeth clenching, headache, fatigue. Rx Only. Please refer to the Instructions for Use or contact us for full safety information.”
​
​For full Indication, Contraindications and Important Safety Information see the detailed labeling or contact Medical Affairs at (310) 479-3100.
References:
1. McGough JJ, Loo SK, Sturm A, et al. An eight-week, open-label pilot feasibility study of trigeminal nerve stimulation in youth with attention-deficit/hyperactivity disorder. Brain Stimulation. 2015;8:299-304.
2. McGough JJ, Sturm A, Cowen J, et al. Double-blind, sham-controlled, pilot study of trigeminal nerve stimulation for attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2019;58(4):403-411.